What is Pelthos Therapeutics Inc.'s market cap?

Pelthos Therapeutics Inc. (PTHS) has a market capitalization of $94.4M and trades on AMEX.

What is Pelthos Therapeutics Inc.'s revenue and profitability?

Pelthos Therapeutics Inc. generated $27.7M in trailing twelve-month revenue with a net loss of $51.6M, representing a net margin of -186.2%. Gross margin stands at 79.6%, with free cash flow of -$16.8M. These figures are based on the Q1 2026 filing.

Who are Pelthos Therapeutics Inc.'s competitors?

Pelthos Therapeutics Inc.'s key competitors include Verrica Pharmaceuticals Inc., Scilex Holding Company Common Stock, Journey Medical Corporation Common Stock, and others. These companies compete in similar markets and product categories.

Who does Pelthos Therapeutics Inc. partner with?

Pelthos Therapeutics Inc.'s notable partners include Ligand Pharmaceuticals, Inc., Orion Corporation, Horizon Technology Finance Corporation, and others.

What subsidiaries does Pelthos Therapeutics Inc. have?

Pelthos Therapeutics Inc.'s subsidiaries include LNHC, Inc., Channel Therapeutics Corporation.

Where is Pelthos Therapeutics Inc. headquartered?

Pelthos Therapeutics Inc. is headquartered in United States of America and employs approximately 11 people. It has been publicly traded since 2024.

Pelthos Therapeutics Inc.

PTHS

Pelthos Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of innovative dermatology and pain management therapies.

Market cap

$94.4M+19.6%

Revenue$27.7M—

Net income-$51.6M-601%

Free cash flow-$16.8M—

EPS (diluted)-$13.44-34.0%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 14, 2026

Revenue$10.9MBeat by $468.3K EPS-$3.09Beat by $0.36

Read the full report

Next report

Aug 12, 2026 (in a month)

Revenue estimate$15.2M

EPS estimate-$2.95

Financials

Q1 2026

Income statement

See full

Revenue$10.9M—

Gross profit$9.2M—

Operating income-$13.1M-614%

Net income-$10.2M-420%

EPS (diluted)-$3.09+3.7%

Balance sheet

See full

Cash & equivalents$32.0M+24,250%

Total debt$29.6M—

Total equity$35.1M+937%

Total assets$145.4M+15,855%

Cash flow

See full

Operating cash flow-$13.1M-1,977%

CapEx$194.0K—

Free cash flow-$13.3M-2,008%

Valuation & ratios

Valuation

See full

Market cap$94.4M+19.6%

Enterprise value$92.07M—

P/S3.4×—

Profitability

See full

Gross margin79.6%—

Operating margin-157.7%—

Net margin-186.2%—

Returns & leverage

See full

Debt / equity0.8×—

Current ratio2.8×+2.6×

Segments

By segment

See full

Commercial operations$10.7M—

Research and Development operations$241.0K—

Competitors

By market cap

Opko Health$1.0B-1.2%

Zevra Therapeutics, Inc.$824.1M+33.7%

Puma Biotechnology$402.1M+129%

Journey Medical Corporation$192.7M—

Verrica Pharmaceuticals Inc.$112.2M+46.1%

PTH

Pelthos Therapeutics Inc.$94.4M+17.6%

Cumberland Pharmaceuticals$90.5M+99.0%

Scilex Holding Company$64.7M+88.5%

By revenue growth

Zevra Therapeutics, Inc.+201%

Journey Medical Corporation+15.0%

Cumberland Pharmaceuticals+2.1%

Opko Health-15.7%

Scilex Holding Company-33.2%

By net margin

Zevra Therapeutics, Inc.101.58%+328pp

Journey Medical Corporation-14.82%+21.2pp

Cumberland Pharmaceuticals-17.6%-9.6pp

Opko Health-36.64%-31.0pp

PTH

Pelthos Therapeutics Inc.-186.23%—

Scilex Holding Company-1,162.43%-1,015pp

Profile

Pelthos Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of innovative dermatology and pain management therapies. The company leverages its proprietary NITRICIL technology platform to deliver nitric oxide-based treatments for viral skin infections and is advancing a pipeline of non-opioid pain therapeutics targeting the NaV1.7 sodium ion channel.

Competitive position

The company holds a unique position as the provider of the first FDA-approved at-home prescription treatment for molluscum contagiosum and maintains a proprietary manufacturing facility for its nitric oxide API.

GeographiesUnited States, Worldwide

Customer segmentsWholesalers, Healthcare Providers, Pediatric Patients

Business modelProduct manufacturing, IP Licensing, Direct sales

SuppliersNitric oxide gas suppliers, Raw material vendors, Contract Manufacturing Organizations (CMOs), Third-party logistics providers

CustomersNational pharmaceutical wholesalers, Regional pharmaceutical wholesalers, Retail pharmacies, Amazon Pharmacy

CountryUnited States of America

Listed2024

Employees11.0

CEOScott Plesha

SectorHealthcare

IndustryBiotechnology

Websitepelthos.com

FilingsSEC EDGAR

Ask your AI about Pelthos Therapeutics Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Pelthos Therapeutics Inc.'s market cap?: Pelthos Therapeutics Inc. (PTHS) has a market capitalization of $94.4M and trades on AMEX.
What is Pelthos Therapeutics Inc.'s revenue and profitability?: Pelthos Therapeutics Inc. generated $27.7M in trailing twelve-month revenue with a net loss of $51.6M, representing a net margin of -186.2%. Gross margin stands at 79.6%, with free cash flow of -$16.8M. These figures are based on the Q1 2026 filing.
Who are Pelthos Therapeutics Inc.'s competitors?: Pelthos Therapeutics Inc.'s key competitors include Verrica Pharmaceuticals Inc., Scilex Holding Company Common Stock, Journey Medical Corporation Common Stock, and others. These companies compete in similar markets and product categories.
Who does Pelthos Therapeutics Inc. partner with?: Pelthos Therapeutics Inc.'s notable partners include Ligand Pharmaceuticals, Inc., Orion Corporation, Horizon Technology Finance Corporation, and others.
What subsidiaries does Pelthos Therapeutics Inc. have?: Pelthos Therapeutics Inc.'s subsidiaries include LNHC, Inc., Channel Therapeutics Corporation.
Where is Pelthos Therapeutics Inc. headquartered?: Pelthos Therapeutics Inc. is headquartered in United States of America and employs approximately 11 people. It has been publicly traded since 2024.